Optellum is the only Lung Nodule AI with named reimbursement by CMS 5 years and running. Our US health system partners are billing and being reimbursed for using Optellum’s Lung Cancer Prediction (LCP) AI today. We help remove the financial risks often associated with cutting-edge AI adoption. While other tools offer promises, Optellum delivers.

In this next topic of our Learning Center Highlight series, we’ll explore why the time between detecting a lung nodule and taking action matters more than ever in lung cancer survival.

Incidental lung nodule care requires more than a one-time risk output. Thoracic programs are multidisciplinary teams comprising pulmonologists, radiologists,...

Incidental lung nodules are managed by multidisciplinary teams, not one specialty alone. Our LCP AI remains the only FDA-cleared AI risk stratification solution indicated for both pulmonologists and radiologists.

My name is Samantha Otis and I am a Nurse Practitioner working with MCG's Lung Cancer Screening Program. I get the opportunity to see patients in clinic through their journey, from discovery to treatment.

As part of today’s Learning Center Highlight, we’re taking a closer look at why timing plays such a critical role in lung cancer survival. It is not just about advancements in treatment, but it is about how early the disease is detected, and the difference can be significant:

Today’s Learning Center Highlight brings us to a frequently ignored aspect of lung cancer discussions: it goes beyond smoking. While smoking remains the leading cause, up to 1 in 4 lung cancer cases globally occur in people who have never smoked.

As National Physicians Week comes to a close, we want to recognize  physicians globally for their unwavering dedication in leading the front lines of lung cancer care. Their work plays a vital role in helping more patients get diagnosed earlier, receive timely intervention, and have better survival outcomes.

In case you missed it, Fierce Biotech covered our pioneering AI-powered lung cancer diagnostic initiative with the NHS. This is the first NHS project to combine our AI-powered lung nodule risk stratification & management platform (Virtual Nodule Clinic) with robotic-assisted bronchoscopy. This programme is designed to help clinicians diagnose lung cancer earlier, more accurately, and…

This World Cancer Day, we strengthen our commitment to transforming early lung cancer diagnosis. At Optellum, we’re harnessing the power of AI to support clinicians in identifying and diagnosing lung cancer earlier, when treatment can be most effective. By empowering clinicians with precision tools to identify and treat high-risk patients earlier, we’re helping transform outcomes…

Lung cancer patients in the US are typically diagnosed through one of two pathways: lung cancer screening or incidentally (i.e., suspicious lung nodule is found on a scan done primarily for another concern). Early detection and diagnosis change the course of lung cancer, and it matters on both pathways. Screening programs (planned, proactive detection) Lung…

Great to see our AI technology featured on the news as a “glimpse of the future” for the NHS. Our Virtual Nodule Clinic sits at the heart of a single, AI- and robot-enhanced end-to-end lung cancer diagnostic pathway that can help find lung cancer early, while reducing costly downstream workflows. This is the kind of…